Comorbidity burden in patients with psoriatic arthritis
Vol 6 Nr 4 (2025), Research articles
Vol 6 Nr 4 (2025)

Comorbidity burden in patients with psoriatic arthritis

Research articles
Publisert oktober 10, 2025
Lucia Dutca
State Medical and Pharmaceutical University ”Nicolae Testemitanu”
Eugeniu RUSSU
Nicolae Testemitanu State University of Medicine and Pharmacy; Timofei Mosneaga Republican Clinical Hospital, Chisinau, Republic of Moldova
Liliana GROPPA
Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova

Sammendrag

Introduction. Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting both the skin and musculoskeletal system, characterized by significant clinical heterogeneity and a substantial comorbidity burden. PsA is associated with increased cardiovascular, metabolic, and autoimmune conditions, yet regional data remain scarce. This study aims to assess the prevalence and impact of comorbidities in PsA patients compared to those with psoriasis alone (PsO).

Material and methods. A prospective cohort study with retrospective components was conducted between 2017 and 2019, including 184 patients: 92 with PsA and 92 with PsO. Clinical, laboratory, and imaging data were analyzed. The prevalence of comorbidities was compared between groups using statistical tests, and logistic regression was applied to identify independent predictors.

Results. Comorbidities were significantly more frequent in PsA (77.2%) than PsO (48.9%) (p<0.05). The prevalence of hypertension (38% vs. 19.6%), osteoarthritis (39.1% vs. 19.6%), type 2 diabetes (8.7% vs. 4.3%), and obesity (25% vs. 13%) was markedly higher in PsA. Increased rates of cardiovascular risk factors, metabolic syndrome, and autoimmune thyroiditis were also identified. This comorbidity burden may reflect a systemic inflammation, thus emphasizing the need for early intervention. 

Conclusions. PsA is a systemic disease with a substantial comorbid burden. A multidisciplinary approach integrating rheumatology, cardiology, and endocrinology is crucial to optimizing patient outcomes. Early recognition and proactive management of comorbid conditions are essential to mitigate long-term disease complications.


|Utsikt: 0|


##submission.license.cc.by4.footer##

##submission.copyrightStatement##

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370